Review
. 2015 Aug; 2015:191832.
doi: 10.1155/2015/191832.

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors

Francesca De Felice 1 Claudia Marchetti 2 Innocenza Palaia 2 Daniela Musio 1 Ludovico Muzii 2 Vincenzo Tombolini 1 Pierluigi Benedetti Panici 2 
Affiliations
  • PMID: 26236750
  •     41 References
  •     23 citations

Abstract

Ovarian cancer is the most important cause of gynecological cancer-related mortality, with the majority of women presenting with advanced disease. Although surgery and chemotherapy can improve survival rates, it is necessary to integrate alternative strategies to improve the outcomes. Advances in understanding the role of immune system in the pathogenesis of cancer have led to the rapid evolvement of immunotherapy, which might establish a sustained immune system response against recurring cancer cells. Recently, it has emerged that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints," which turn off the immune system. Similarly, cancer cells are able to use these checkpoints to avoid immune control and rejection. Inhibition of these inhibitory pathways represents a potent strategy in the fight against cancer and is currently under investigation with encouraging results in some cancers, such as melanoma. In ovarian cancer researches are still in an early phase, but with promising results. In this review we will explore the rationale of immunotherapy in ovarian cancer with a special focus on these emerging molecules.

Checkpoint blocking antibodies in cancer immunotherapy.
Chrisann Kyi, Michael A Postow.
FEBS Lett, 2013 Oct 29; 588(2). PMID: 24161671
Highly Cited. Review.
Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.
P S Linsley, J Bradshaw, +3 authors, R S Mittler.
Immunity, 1996 Jun 01; 4(6). PMID: 8673700
Highly Cited.
Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Lana E Kandalaft, Gregory T Motz, Jaikumar Duraiswamy, George Coukos.
Cancer Metastasis Rev, 2011 Feb 08; 30(1). PMID: 21298574
Review.
Checkpoint inhibitors in immunotherapy of ovarian cancer.
Dong-hui Wang, Liang Guo, Xiao-hua Wu.
Tumour Biol, 2014 Nov 21; 36(1). PMID: 25409618
Review.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Current status of adoptive immunotherapy of cancer.
A E Chang, S Shu.
Crit Rev Oncol Hematol, 1996 Apr 01; 22(3). PMID: 8793276
Review.
Natural innate and adaptive immunity to cancer.
Matthew D Vesely, Michael H Kershaw, Robert D Schreiber, Mark J Smyth.
Annu Rev Immunol, 2011 Jan 12; 29. PMID: 21219185
Highly Cited. Review.
Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
Ramez N Eskander, Krishnansu S Tewari.
Clin Ther, 2015 Jan 17; 37(1). PMID: 25592089
Review.
Activation rules: the two-signal theories of immune activation.
Alan G Baxter, Philip D Hodgkin.
Nat Rev Immunol, 2002 Jul 03; 2(6). PMID: 12093010
Review.
Immunotherapy in gastric cancer.
Satoko Matsueda, David Y Graham.
World J Gastroenterol, 2014 Mar 04; 20(7). PMID: 24587645    Free PMC article.
Review.
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth.
Science, 2011 Mar 26; 331(6024). PMID: 21436444
Highly Cited. Review.
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, +8 authors, T Honjo.
Science, 2001 Feb 24; 291(5502). PMID: 11209085
Highly Cited.
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
T Takahashi, T Tagami, +5 authors, S Sakaguchi.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899917    Free PMC article.
Highly Cited.
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
Edward F McCarthy.
Iowa Orthop J, 2006 Jun 23; 26. PMID: 16789469    Free PMC article.
Highly Cited.
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
Margaret K Callahan, Jedd D Wolchok.
J Leukoc Biol, 2013 May 15; 94(1). PMID: 23667165    Free PMC article.
Highly Cited. Review.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Immune modulation in cancer with antibodies.
David B Page, Michael A Postow, +2 authors, Jedd D Wolchok.
Annu Rev Med, 2013 Nov 06; 65. PMID: 24188664
Highly Cited. Review.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
Immunotherapy for ovarian cancer: what's next?
Lana E Kandalaft, Daniel J Powell, Nathan Singh, George Coukos.
J Clin Oncol, 2010 Nov 17; 29(7). PMID: 21079136    Free PMC article.
Review.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, +16 authors, T Honjo.
J Exp Med, 2000 Oct 04; 192(7). PMID: 11015443    Free PMC article.
Highly Cited.
II. Contribution to the Knowledge of Sarcoma.
W B Coley.
Ann Surg, 1891 Sep 01; 14(3). PMID: 17859590    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Suzanne L Topalian, Mario Sznol, +18 authors, F Stephen Hodi.
J Clin Oncol, 2014 Mar 05; 32(10). PMID: 24590637    Free PMC article.
Highly Cited.
New insights into ovarian cancer pathology.
J Prat.
Ann Oncol, 2012 Sep 26; 23 Suppl 10. PMID: 22987944
Highly Cited.
Cancer statistics, 2015.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2015 Jan 07; 65(1). PMID: 25559415
Highly Cited.
Programmed death-1 pathway in cancer and autoimmunity.
Ariel Pedoeem, Inbar Azoulay-Alfaguter, +2 authors, Adam Mor.
Clin Immunol, 2014 May 02; 153(1). PMID: 24780173
Highly Cited. Review.
Cancer immunotherapy: current status and future directions.
Fumito Ito, Alfred E Chang.
Surg Oncol Clin N Am, 2013 Sep 10; 22(4). PMID: 24012398
Review.
PD-1 inhibitors raise survival in NSCLC.
Cancer Discov, 2014 Jan 10; 4(1). PMID: 24402925
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Properties of mouse and human IgG receptors and their contribution to disease models.
Pierre Bruhns.
Blood, 2012 Apr 27; 119(24). PMID: 22535666
Highly Cited. Review.
Specificity in cancer immunotherapy.
Andrea Schietinger, Mary Philip, Hans Schreiber.
Semin Immunol, 2008 Aug 08; 20(5). PMID: 18684640    Free PMC article.
Review.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Mechanisms of CTLA-4-Ig in tolerance induction.
M-L Alegre, F Fallarino.
Curr Pharm Des, 2006 Feb 04; 12(2). PMID: 16454732
Review.
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
David F Stroncek, Carolina Berger, +15 authors, Cornelis J M Melief.
J Transl Med, 2012 Mar 17; 10. PMID: 22420641    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
New Approaches for Immune Directed Treatment for Ovarian Cancer.
Nicola Hardwick, Paul H Frankel, Mihaela Cristea.
Curr Treat Options Oncol, 2016 Mar 05; 17(3). PMID: 26942589
Review.
Monocyte and interferon based therapy for the treatment of ovarian cancer.
Daniel S Green, Ana T Nunes, Christina M Annunziata, Kathryn C Zoon.
Cytokine Growth Factor Rev, 2016 Mar 31; 29. PMID: 27026228    Free PMC article.
Anti-angiogenic agents in ovarian cancer: past, present, and future.
B J Monk, L E Minion, R L Coleman.
Ann Oncol, 2016 May 04; 27 Suppl 1. PMID: 27141068    Free PMC article.
Review.
Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.
Andreas Heindl, Chunyan Lan, +2 authors, Yinyin Yuan.
Oncotarget, 2016 Sep 24; 7(44). PMID: 27661102    Free PMC article.
Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer.
Jiangdong Xiang, Lina Zhou, +5 authors, Xiaoping Wan.
Transl Oncol, 2016 Nov 27; 10(1). PMID: 27888711    Free PMC article.
Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.
Kathryn Mills, Katherine Fuh.
F1000Res, 2017 Feb 12; 6. PMID: 28184293    Free PMC article.
Review.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Xinxin Zhu, Jinghe Lang.
J Gynecol Oncol, 2017 Jun 29; 28(5). PMID: 28657225    Free PMC article.
Review.
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.
Franziska Eckert, Ivan Jelas, +8 authors, Karin Schilbach.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680762    Free PMC article.
Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.
F Eckert, U S Gaipl, +4 authors, D Zips.
Clin Transl Radiat Oncol, 2017 Feb 04; 2. PMID: 29657997    Free PMC article.
Review.
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, +7 authors, Patrick J Stiff.
J Ovarian Res, 2018 May 31; 11(1). PMID: 29843813    Free PMC article.
Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer.
Yanming Sun, Zhitao Yao, +5 authors, Chuntao Sun.
Exp Ther Med, 2018 Aug 18; 16(2). PMID: 30116358    Free PMC article.
Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.
Hong Liao, Hongmei Zhu, Shanling Liu, He Wang.
Oncol Lett, 2018 Aug 22; 16(3). PMID: 30127950    Free PMC article.
VISTA expressed in tumour cells regulates T cell function.
Kumuluzi Mulati, Junzo Hamanishi, +14 authors, Masaki Mandai.
Br J Cancer, 2018 Nov 02; 120(1). PMID: 30382166    Free PMC article.
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches.
Innocenza Palaia, Federica Tomao, +2 authors, Pierluigi Benedetti Panici.
Onco Targets Ther, 2020 Jul 04; 13. PMID: 32617007    Free PMC article.
Review.
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Lucia Musacchio, Serena Maria Boccia, +9 authors, Violante Di Donato.
J Clin Med, 2020 Jun 07; 9(6). PMID: 32503218    Free PMC article.
Review.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Immune check-point in endometrial cancer.
Francesca De Felice, Claudia Marchetti, Vincenzo Tombolini, P Benedetti Panici.
Int J Clin Oncol, 2019 May 03; 24(8). PMID: 31049759
Review.
Ovarian Cancer-Associated Ascites Have High Proportions of Cytokine-Responsive CD56bright NK Cells.
Cláudia Rodrigues Tonetti, Caroline Natânia de Souza-Araújo, +6 authors, Fernando Guimarães.
Cells, 2021 Aug 08; 10(7). PMID: 34359872    Free PMC article.
Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma.
Fanglu Qin, Shenghua Lin, +7 authors, Shikang Li.
World J Surg Oncol, 2021 Sep 16; 19(1). PMID: 34521431    Free PMC article.
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.
Lilia Bardoscia, Nadia Pasinetti, +2 authors, Angela Sardaro.
Front Pharmacol, 2021 Nov 19; 12. PMID: 34790123    Free PMC article.
Review.
Integrated Analysis of Ferroptosis-Related Biomarker Signatures to Improve the Diagnosis and Prognosis Prediction of Ovarian Cancer.
Huan Wang, Qi Cheng, +2 authors, Xiaofang Yi.
Front Cell Dev Biol, 2022 Jan 25; 9. PMID: 35071242    Free PMC article.
Overexpression of CAPG Is Associated with Poor Prognosis and Immunosuppressive Cell Infiltration in Ovarian Cancer.
Senwei Jiang, Yuebo Yang, +4 authors, Xiaomao Li.
Dis Markers, 2022 Feb 22; 2022. PMID: 35186171    Free PMC article.